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SObjective: The objective of this study was to detect and evaluate reliable metabolite markers for screening and
monitoring treatment of patients with esophageal adenocarcinoma (EAC) by studying metabolomics. The sen-
sitivity and specificity of the study were evaluated not only for EAC but also for Barrett esophagus and high-
grade dysplasia, which are widely regarded as precursors of EAC.
Methods: Profiles of metabolites in blood serum were constructed using nuclear magnetic resonance spectros-
copy and statistical analysis methods. The metabolite biomarkers discovered were selected to build a predictive
model that was then used to test the classifications accuracies.
Results: Eight metabolites showed significant differences in their levels in patients with cancer and in the con-
trol group on the basis of Student t test. A partial least-squares discriminant analysis model built on these me-
tabolites provided excellent classifications of patients with cancer and the control group, with the area under the
receiver operating in a characteristic curve of>0.85 for both training and validation sample sets. Evaluated by
the same model, the Barrett esophagus samples were of mixed classification, and the high-grade dysplasia sam-
ples were classified primarily as cancer samples. A pathway study indicated that altered energy metabolism and
changes in the trochloroacetic acid cycle were the dominant factors in the biochemistry of EAC.
Conclusions: 1H nuclear magnetic resonance–based metabolite profiling analysis was shown to be an effective
approach to differentiating between patients with EAC and healthy subjects. Good sensitivity and selectivity
were shown by using the 8metabolitemarkers discovered to predict the classification of samples from the healthy
control group and the patients with the disease. Serummetabolic profiling may have potential for early diagnosis
of EAC and may enhance our understanding of its mechanisms. (J Thorac Cardiovasc Surg 2011;141:469-75)Supplemental material is available online.
Esophageal cancer (EC) is a leading cause of death from
cancer worldwide. The two principal types of EC, squa-
mous cell carcinoma and adenocarcinoma, are relatively
uncommon in the United States, composing approximately
1% of all cancers. However, the incidence of adenocarci-
noma is rising at a rapid rate. According to a report from
the American Cancer Society, 12,300 new cases and
12,100 deaths were reported in 2000,1 and the correspond-
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The Journal of Thoracic and Catively.2 The 5-year survival rates of those with localized
and all stages combined are 34% and 17%, respectively.2
Moreover, currently there is no reliable method of early
detection or of prediction of treatment outcome.
Barrett’s esophagus (BE), high-grade dysplasia (HGD),
and invasive cancer are thought to compose a multistep pro-
cess in the development of esophageal adenocarcinoma
(EAC).3 HGD has been considered to be the immediate pre-
cursor of invasive adenocarcinoma.4 Most patients with
HGD are usually bearing or developing cancer,5 so HGD
has been regarded as a marker of progression to carcinoma.6
However, no intervention currently in existence prevents
the progression of BE or HGD to esophageal cancer.5 The
traditional methods of diagnosing EC include endoscopy
and barium swallow,7 but the poor specificity and sensitivity
of these methods results in the detection of EC only at
advanced stages. Recently, prognostic and predictive pro-
tein and genetic markers have been introduced to aid in
the diagnosis of EC.8,9 However, markers effective at
a potentially curative stage are lacking.
Metabolomics, a growing field in systems biology, offers
a powerful and promising approach to identifying valuable
biomarkers. Metabolomics (or metabolite profiling) de-
scribes the study of concentrations and fluxes of low molec-
ular weight metabolites present in biofluids or tissues that
provide detailed information about biologic systems and
their current status.10,11 The information-rich analyticrdiovascular Surgery c Volume 141, Number 2 469
Abbreviations and Acronyms
AUC ¼ area under the curve
BE ¼ Barrett’s esophagus
EAC ¼ esophageal adenocarcinoma
EC ¼ esophageal cancer
GC/MS ¼ gas chromatography/mass
spectrometry
HGD ¼ high-grade dysplasia
LV ¼ latent variable
MS ¼ mass spectrometry
NMR ¼ nuclear magnetic resonance
PLS ¼ partial least-squares
PLSDA ¼ partial least-squares discriminant
analysis
ROC ¼ receiver operating characteristic
TCA ¼ citrate cycle
TSP ¼ trimethylsilylpropionic acid-d4 sodium
salt
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Stechniques of nuclear magnetic resonance (NMR) spectros-
copy and mass spectrometry (MS) combined with multivar-
iate statistical analyses are the premier methods for
metabolomics-based studies.12 Various diseases, including
but not limited to cancers, diabetes, inborn errors of metab-
olism, and coronary heart disease, have been explored using
metabolomics as a tool, and a number of putative bio-
markers have been detected and evaluated with the goal
of improved diagnoses, assessment of risk, and even predic-
tion of therapy outcomes.11 A recent example is the identi-
fication of sarcosine as a potential marker for prostate tumor
aggressiveness; it was discovered using a metabolomics ap-
proach.13 However, few metabolomics studies of EC have
been reported to date. Recently, Shen and coworkers re-
ported 20 metabolite markers that were detected in fresh tu-
mor tissue and corresponding normal esophageal mucosa
by using gas chromatography/mass spectrometry (GC/
MS).14 To decrease the mortality rate of patients with
esophageal cancer, development of early diagnostic
methods, especially the exploitation of biomarkers that of-
fer high sensitivity and specificity, is still in great demand.
In addition, information provided by metabolomics in the
area of biology may be useful in further understanding the
biology of the disease.
In this study, 1H NMR and multivariate statistical analy-
sis were employed to detect molecular changes in human
blood serum samples by comparing the metabolic profiles
of patients with BE, HGD, and EAC as well as of normal
controls in an attempt to identify a metabolite profile of
EAC. We also attempted to identify a set of putative
markers that may be useful in understanding the pathogen-
esis of EAC.470 The Journal of Thoracic and Cardiovascular SurgMATERIALS AND METHODS
Chemicals
Deuterium oxide (D2O, 99.9% D) was purchased from Cambridge Iso-
tope Laboratories, Inc. (Andover, Mass), and trimethylsilylpropionic acid-
d4 sodium salt (TSP) was purchased from Sigma-Aldrich (Milwaukee,
Wis). All chemical reagents were analytic grade.Serum Sample Collection and Storage
All work was conducted under a protocol approved by the Indiana Uni-
versity School of Medicine and Purdue University Institutional Review
Board. All subjects included in the study provided informed consent ac-
cording to institutional guidelines. All samples were collected when sub-
jects were in the fasting state. Whole blood samples were collected from
patients with histologically documented BE (n ¼ 5), BE with HGD
(n ¼ 11), and adenocarcinoma (n ¼ 68). Blood samples from 34 healthy
volunteers served as controls. Each blood sample was allowed to clot for
45 minutes and then was centrifuged at 2000 rpm for 10 minutes. The se-
rumwas collected, and an aliquote was put into in a separate vial and stored
at –80C until use.1H NMR and Statistical Analysis
Samples were prepared by mixing 200 mL serum with 330 mL D2O. A
60-mL solution of TSP (0.12 mg/mL) sealed in a separate capillary was
used as an internal standard, which acted as the frequency standard
(d ¼ 0.00). A Bruker DRX 500-MHz spectrometer equipped with
a room-temperature hydrogen cyanide probe was used to acquire 1-dimen-
sional 1H NMR spectra. The water signal was suppressed using a standard
1-dimensional Carr-Purcell-Meiboom-Gill pulse sequence coupled with
water presaturation. For each spectrum, 64 transients were collected, and
16K data points were acquired using a spectral width of 6000 Hz. An ex-
ponential weighting function corresponding to 1 Hz line broadening was
applied to the free-induced decay before Fourier transformation. Phasing
and baseline correction were applied using Bruker TopSpin software.
To remove the errors resulting from the small fluctuations of chemical
shifts due to pH or ion concentration variations, NMR spectral regions
were binned to 4K buckets of equal width (1.5 Hz). Each spectrum was
aligned to the methyl peak of alanine at 1.48 ppm, and was normalized us-
ing the integrated TSP signal. Spectral regions within the range of 0.3 to 10
ppmwere used after deleting the region containing thewater resonance and
urea signal (4.5 to 6. ppm).
To visualize the differences between spectra better, partial least-squares
(PLS), a robust supervised method to detect subtle changes between group
variations, was employed. PLS fits data matrices X (which consists of
NMR spectra) and Y (which is set to 1 for cancer and 0 for control) and re-
casts these data as score plots and loading plots. The NMR spectral signals,
or variables, were autoscaled (by subtracting the mean value of each vari-
able and dividing by its standard deviations) prior to all statistical analyses.
The score plot shows the possible relationships (or clustering) among the
samples to estimate the classification; each orthogonal axis is named a la-
tent variable (LV). The corresponding loading plot of each LV contains the
weight or contribution of each variable in the modeling. To explore poten-
tial biomarker candidates, univariate analysis was performed by calculating
the P value (unpaired Student t test) and a Benjamini-Hochberg correction
was followed in order to control false discovery errors originating from
multiplicity.15
Subsequently, a partial least-squares discriminant analysis (PLS-DA)
model was built to evaluate the biomarker candidates when combined as
a metabolite profile. Predictions were made visually using a Y-predicted
scatter plot with a cut-off value chosen for potential class membership.
The NMR data were imported into Matlab (R2008a; MathWorks, Natick,
Mass) and installed using a PLS toolbox (version 4.1; Eigenvector Re-
search, Inc.) for PLS and PLS-DA analysis.ery c February 2011
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FIGURE 1. PLS score plot based on the 1H NMR spectra of normal sub-
jects, BE, HGD and esophageal cancer patients.
TABLE 1. Clinicopathologic characteristics of patients with
esophageal cancer
Training group (G1) Test group (G2)
Patient
no. Age Sex cStage
Patient
no. Age Sex cStage
1 69 F T3N1 1 66 M T3N1
2 69 M T1N0 2 60 M T3N1
3 63 M T3N1 3 64 M T3N1
4 71 M T1N0 4 58 F T4N1
5 77 M T3N1 5 68 M M
6 49 M M 6 46 M M1a
7 78 M T3N1 7 78 M T3N1
8 61 M M 8 78 M T1N0
9 69 M T1N0 9 66 M T3N1
10 57 F T1N0 10 53 M T2N0
11 65 M T3N1M1a 11 54 F T3N1M1a
12 60 F T2N0 12 62 M T1N0
13 68 M unk 13 59 F unk
14 51 M unk 14 75 M T3N0
15 47 F T3N0 15 78 M T2N1
16 56 M T2N1M1a 16 72 M T3N0
17 71 M T2Nx 17 77 F T3N0
18 58 M unk 18 72 M unk
19 91 M T3N0 19 82 F T3N1M1b
20 74 M T3N1M1a 20 58 M T3N1
21 62 M T3N1 21 67 M T3N1
22 64 M T3N1 22 67 M T3N1M1
23 53 M T2N1M1 23 77 M T1N0
24 54 M T2N1M1a 24 62 M T3N1
25 64 F T3N1 25 67 M T3Nx
26 72 M T3N1M1a 26 54 M T3N1
27 64 M T3N1 27 72 M T3N1
28 71 M T2N0 28 67 M T3N1M1
29 65 M T3N0 29 66 M unk
30 57 M T3N1M1a 30 64 M T2N1M1
31 78 M T4N1 31 71 M T3N1M1
32 66 M T2N1 32 68 M T3
33 74 M T3N3M1 33 62 F T2N1
34 63 M T3N1 34 61 M T2Nx
cStage, Clinical stage; UNK, unknown.
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SRESULTS
Representative 1H NMR spectra of samples from the con-
trol group and the esophageal cancer group are shown in
Figure E1, along with a difference spectrum that shows
only a moderate amount of difference among the spectra.
However, cancerous and control samples could be clearly
separated when contributions from many signals in the
spectra were combined, as illustrated in the PLS score
plot shown in Figure 1. Also, and this is promising, the
BE and HGD samples appeared in the middle of the cluster
of control and cancer samples in the same plot. HGD sam-
ples were generally closer to the cluster of the cancer sam-
ples. However, examination of the PLS loadings indicated
that a large number of low-level signals contributed and
few easily detected signals dominated.
To explore and evaluate potential biomarker candidates
better, all the control and esophageal cancer samples were
randomly and equally divided into 2 groups: G1, the train-
ing group; and G2, the test group (Table 1). For the G1 sam-
ples, P values were calculated for all data points. There
were 19 spectral regions that showed a statistical difference
between cancer and control (uncorrected P value< .05);
they were identified and integrated. P values along with
a Benjamini-Hochberg correction were calculated for the
integrated peaks, and 14 peakswith a correctedP value<.05
were short-listed (Table E1). According to the literature,16
these peaks belonged to 8 potential biomarker candidates,
which were identified as b-hydroxybutyrate, lysine, gluta-
mine, citrate, creatinine, lactate, glucose, and an unknown
molecule. The same metabolite peaks in G2 were also inte-
grated. Fold changes were calculated by dividing the aver-
age cancer values by the average control values. All the
metabolite concentrations collected were higher in the can-
cer samples, as shown in Table 2.The Journal of Thoracic and CaPLS-DA was then used to build a multivariate model to
evaluate the potential biomarker candidates together. The
8 metabolites in the G1 samples were selected as the vari-
ables to build the PLS-DA model. Leave-one-out cross-val-
idation was performed to obtain the best model and avoid
overfitting. Three LVs were used and the cross-validation
error was estimated to be 14.7%. The model was then reap-
plied to the samples in G2. The PLS-DA score plots of G1
and G2 are shown in Figure 2, A, and 2, B, respectively.
Most samples were well classified using a cut-off of
0.0855. In Figure 2, C, and 2, D, receiver operating charac-
teristic (ROC) curve analysis using the cross-validated pre-
dicted Y (predicted class) values was utilized to judge the
sensitivity and specificity of the PLS-DA model. The areardiovascular Surgery c Volume 141, Number 2 471
TABLE 2. Metabolites showing a significant separation of control
samples from cancer samples in the training group and their fold
change values
Metabolite P value* Fold change
Glutamine 3.02E–02 1.10
b-Hydroxybutyrate 2.28E–05 1.31
Citrate 3.31E–04 1.26
Unknown 2.97E–05 1.26
Lysine 9.63E–04 1.10
Creatinine 2.19E–02 1.23
Lactate 2.66E–03 1.28
a-Glucose 1.49E–04 1.20
*Benjamini-Hochberg correctionwas used to control for possible false discovery result-
ing from the use of multiple variable comparison. In this case 19 variables were used.
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Sunder the curve (AUC) of G1 and G2 were 0.875 and 0.888,
respectively. The sensitivity and specificity for the detection
of EC were 88% and 82% for G1 and 88% and 92% for
G2, respectively.FIGURE 2. Results of the PLS-DA model from the 8 metabolite markers for (
cross-validated predicted class values for (C) G1 and (D) G2. The AUC of G1
472 The Journal of Thoracic and Cardiovascular SurgMetabolic differences might act as a useful tool for grad-
ing tumors compared with the classical individual
metabolite-based targeted analysis, so P values and box-
and-whisker plot studies were employed to try to use the
metabolite profile to identify patients with early-stage dis-
ease. The P value results of various group comparisons of
control, BE, HGD, and cancer samples are listed in Table
E2. The low P values of the metabolites for all the control
and cancer samples demonstrated that the levels of these
molecules were statistically different. However, P values
between adjoining stages were always high, indicating
that metabolite changes from one stage to the next stage
were not significant.
Comparing HGD with controls, changes in the concen-
trations of citrate, creatinine, lactate, glucose, and the un-
known species were notable according to the P values;
and the levels of b-hydroxybutyrate, lysine, and glutamine
changed significantly between BE and cancer. The rangesA) training group (G1) and (B) test group (G2), and ROC curves using the
and G2 are 0.875 and 0.888, respectively.
ery c February 2011
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Sof concentration of each metabolite in samples from con-
trol, HGD, and cancer are shown as box-and-whisker plots
in Figure E2. The BE data were excluded from this plot be-
cause of the small number of samples. The same increasing
trends of each metabolite showed in the plots from normal
to HGD to cancer. For citrate, creatinine, lactate, and glu-
cose, the changes between normal and HGD were greater
than the changes between HGD and cancer, which were
consistent with the P value results. The possible effects of
age and gender were also investigated in the cancer samples
(Table E3). Large P values were observed between male
and female patients for each of the eight markers, indicating
that gender is not likely to be a significant factor in the clas-
sification. Similarly, P values comparing younger and older
patients are also high, indicating that an age effect is also
not likely to be present.
To further evaluate the BE and HGD samples, the same
PLS-DA model used for predicting the control and cancer
samples was applied, and the result is shown in Figure 3.
BE samples gave a mixed result, and no confident conclu-
sion could be made because of the small number of samples.
However, 9 of 11 HGD samples were predicted to be cancer
in this case, which supported the previous PLS result.G
TDISCUSSION
A metabolomics approach based on 1H NMR coupled
with multivariate statistical methods such as PLS or PLS-
DA and starting with a metabolite identified by employing
a univariate statistical method (P values) provides a power-
ful approach to metabolic profiling of blood serum to differ-
entiate patients with EAC from control subjects. Although
the patients with esophageal cancers were easily distin-
guished from control subjects by PLS using autoscaling,
when using other scaling methods (Pareto or log scaling),
this approach was not very successful. This result is ex-
plained by the contribution of a number of low-intensity sig-
nals that can contribute to the classification, depending on
the particular scaling method used. However, significant–1.2
-1
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-0.4
-0.2
0
0.2
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0 5 10 15 20 BE
HGD
cut-off
FIGURE 3. PLS-DA prediction from the model based on 8 metabolite
markers for BE and HGD samples.
The Journal of Thoracic and Canoise also contributes to the low signals that are unidentifi-
able by standard NMR techniques. Using the same model
without including the healthy controls failed to discriminate
differing ages and genders of patients with EC (data not
shown), which indicates that age and gender were probably
not relevant parameters in the model. However, a targeted
approach using 8 detected biomarker candidates (the vast
majority of which can be identified easily) that exhibit
low P values appears to be a good starting place for multi-
variate model building. The model had high sensitivity and
specificity for the prediction of EAC.
Altered pathways in EAC were identified based on the
metabolites that showed significant concentration changes.
Based on the Kyoto Encyclopedia of Genes and Genomes
database (http://www.genome.jp/kegg/pathway.html), a sim-
plified pathway map is shown in Figure 4. The upregulation
of glucose and lactate, a common observation in the serum of
cancer subjects, was detected in samples from patients with
EC. The phenomenon of cancer cells’ avidly taking up glu-
cose and producing lactic acid under aerobic conditions
was hypothesized as being aerobic glycolysis by Otto War-
burg in1924.17Themetabolizationofglucosewith a concom-
itant increase of lactate production has been regarded as
a common trait in many rapidly proliferating cancers. A con-
tinuous supply of glucose is demanded by cancer cells to pro-
duce glycoproteins, triglycerides, and glycogen and as an
important source of energy. High molar concentrations of
lactate were indicated to be correlated with a high incidence
of distantmetastasis, even in an early stage of the disease.Nu-
merous recent reports support these data by demonstrating
various biologic activities of lactate that can enhance the ma-
lignant behavior of cancer cells, including epithelial ovarian
cancer,18 cervical cancer,19 colorectal cancer,20 and various
primary carcinomas in the head, neck, and colorectal re-
gions.21 Thus, glucose and lactate accumulation mirrors the
higher energy demand of tumor malignancy. The average ab-
solute concentration of glucose is above the normal range in
cancer patients; however, its counterpart, lactate, is neverthe-
less roughly within the normal range, so these markers indi-
vidually do not point to abnormality (Table E4).
The organic acids b-hydroxybutyrate and citrate were
also found to be higher in patients with EAC compared to
subjects without EAC. Increased amounts of b-hydroxybu-
tyrate may be to the result of increased energy metabolism
in the tumor, which results in large amounts of lactate being
produced by the tumor.22When lactate is abundant, the Cori
cycle might not be able to convert lactate back into glucose
in the liver, which results in the accumulation of acetyl-CoA
and the citrate upregulation in the citrate cycle (TCA cycle)
sequentially.23 If the acetyl-CoA is not well accommodated
by the TCA cycle, ketogenesis takes place. As a ketone
body, b-hydroxybutyrate is converted by b-hydroxybuty-
rate dehydrogenase, which results in increased levels of
b-hydroxybutyrate.22rdiovascular Surgery c Volume 141, Number 2 473
FIGURE 4. Simplified altered metabolism pathways for the most relevant metabolic differences between patients with esophageal cancer and control sub-
jects. The metabolites in gray were the biomarkers observed as being upregulated in patients with esophageal cancer.
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SHigher levels of lysine, glutamine, and creatinine were
also found in the serum of subjects with EC. This is consis-
tent with the effects on the TCA cycle and lactate accumu-
lation, which provide precursors for many compounds,
including lysine, glutamine, and creatinine. It has been re-
ported that the human hepatocellular carcinoma tumors pro-
duce levels of glutamine that are higher than those found in
noninvolved adjacent liver tissues.24 Elevated levels of ly-
sine are also in close agreement with previous findings in
the extracellular fluid of patients with cerebral gliomas25
and colon carcinomas.26 Creatinine levels are known to be
affected by various cancers, and they were recently ob-
served to be high in a report analyzing tumor samples
from patients with oral squamous cell carcinoma.27 Never-
theless, the absolute concentrations of creatinine and gluta-
mine were also not particularly unusual (Table E4).Limitations
A limitation of the current study is the fact that peaks
generated by different species often overlap in 1H NMR
spectra, especially in the aliphatic region (1–5 ppm). As a re-
sult, potentially important compounds present at smaller
concentrations may be overshadowed by larger peaks and
may be hard to detect. As can be seen in the PLS analysis,474 The Journal of Thoracic and Cardiovascular Surga separation between patients with BE and HDG and the dif-
ferentiation between them and controls without cancer are
possible, but these separations rely on the detection of spe-
cies that occur in lower concentrations. The combination of
NMR with other analytic platforms such as MS will
broaden the ability to detect lower-concentration bio-
markers and, it is hoped, allow more reliable metabolite
profiles to be constructed.12 Future work will focus on the
use of LC/MS and GC/MS analyses to discover other poten-
tial biomolecules. The analysis of additional clinical sam-
ples may allow us to differentiate more successfully
among BE, HGD, and EC as well as to provide information
about staging, which is currently not possible.CONCLUSIONS
1H NMR-based metabolite profiling analysis has been
shown to be an effective approach to differentiating patients
with EAC from healthy subjects. HGD and BE were also
evaluated using the profile developed from serum metabo-
lites, and these conditions could be classified as falling be-
tween cancer and normal, as might be expected on the basis
of their known relationship with the disease. We discovered
8 metabolite markers, including glucose, lactate, citrate,
b-hydroxybutyrate, lysine, glutamine, creatinine, and oneery c February 2011
Zhang et al General Thoracic Surgeryunknown metabolite, with good discriminating ability and
low P values. The results indicate that alteration of energy
metabolism coupled with changes in TCA cycle were dom-
inant in the biochemistry of EAC. Good sensitivity and se-
lectivity were shown in the use of these markers to predict
whether the samples came from the healthy control group
or the subjects with disease. These results indicate the
promise of this approach in developing a profile for earlier
detection. The analysis of additional samples and the use of
additional spectroscopic methods such as MS are expected
to result in the foundation that will allow for an improved
diagnostic assay.G
T
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FIGUREE1. Typical 1H NMRCPMG serum spectra from a healthy volunteer and a patient with esophageal cancer (bottom), and their difference spectrum
(top).
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FIGURE E2. Box-and-whisker plots of the candidate markers. The y-axis represents the relative concentration level of each metabolite normalized by the
internal standard TSP.
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TABLE E1. Summary of spectral regions influencing separation of control samples from cancer samples in the training group.
Chemical shift (d)* Multiplicity* Assignment P value Benjamini-Hochbergy correction
1.20 d b-hydroxybutyrate 4.99E–03 7.90E–03
1.69 m Lysine 6.59E–04 1.57E–03
1.91 m Lysine 4.61E–04 1.25E–03
2.09 m Glutamine 2.22E–02 3.02E–02
2.31 m b-Hydroxybutyrate 2.25E–05 1.42E–04
2.35 m b-Hydroxybutyrate 2.99E–03 5.16E–03
2.39 m b-Hydroxybutyrate 2.40E–06 2.28E–05
2.53 d Citrate 8.70E–05 3.31E–04
2.63 m Unknown 1.56E–06 2.97E–05
2.69 d Citrate 6.82E–04 1.44E–03
3.00 t Lysine 3.04E–04 9.63E–04
4.05 s Creatinine 1.50E–02 2.19E–02
4.11 q Lactate 1.40E–03 2.66E–03
5.22 d a-Glucose 3.15E–05 1.49E–04
*The chemical shift and multiplicity are NMR-dependent quantities that indicate the spectral peak position and number of peaks, respectively, that allow the spectroscopist to
identify the chemical compound (s, singlet; d, doublet; t, triplet; q, quartet;m, complex multiplet). yThe Benjamini-Hochberg correction is used to reduce the false discovery rate
by adjusting the P value to take into account the use of multiple variable comparisons.
TABLE E2. Student t test results for comparison of various groups
Metabolite N vs BE N vs HGD N vs C BE vs HGD BE vs C HGD vs C
Glutamine 1.38E–01 3.42E–01 3.86E–04 6.54E–02 2.07E–02 1.58E–01
b-Hydroxybutyrate 6.62E–01 2.39E–02 3.34E-12 1.54E–01 3.08E–02 3.40E–01
Citrate 8.95E–01 4.86E–03 1.36E–07 1.95E–01 2.00E–01 8.99E–01
Unknown 4.39E–01 1.10E–02 4.67E-10 5.10E–02 1.42E–02 6.38E–02
Lysine 2.36E–01 6.77E–02 1.99E–05 9.96E–01 7.84E–01 6.66E–01
Creatinine 8.59E–01 2.10E–02 5.46E–04 1.05E–01 9.77E–02 9.32E–01
Lactate 1.74E–01 8.21E–04 4.82E–07 5.29E–01 6.09E–01 5.65E–01
a-Glucose 3.80E–01 2.95E–02 2.01E–06 5.83E–01 6.71E–01 4.08E–01
BE, Barrett’s esophagus; C, esophageal cancer; HGD, high-grade dysplasia; N, normal sample.
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TABLE E3. P value results for varying genders and ages of the cancer
patients
Metabolite M vs F
Above-average age vs
below-average age*
Glutamine 0.494 0.888
b-Hydroxybutyrate 0.559 0.329
Citrate 0.063 0.083
Unknown 0.395 0.935
Lysine 0.327 0.974
Creatinine 0.054 0.118
Lactate 0.925 0.889
a-Glucose 0.855 0.344
M, male patient; F, female patient. *Average age of all cancer patients ¼ 65.6 yrs
TABLE E4. Absolute concentration comparison of glutamine,
creatinine, lactate, and glucose
Normal samples EAC samples Normal range
Metabolite
mean
(mM)
SD
(mM)
mean
(mM)
SD
(mM) (mM)*
Glutamine 0.469 0.054 0.515 0.068 0.502–0.670
Creatinine 0.078 0.015 0.096 0.036 0.050–0.093
Lactate 2.86 0.64 3.66 0.79 1.42–4.53
Glucose 5.49 0.76 6.61 1.48 4.90–5.70
SD, standard deviation. *http://www.hmdb.ca/
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